The parasite Plasmodium falciparum causes severe malaria and is the most dangerous to humans. However, it exhibits resistance to their drugs. Farnesyltransferase has been identified in pathogenic protozoa of the genera Plasmodium and the target of farnesyltransferase includes Ras family. Therefore, the inhibition of farnesyltransferase has been suggested as a new strategy for the treatment of malaria. However, the exact functional mechanism of this agent is still unknown. In addition, the effect of farnesyltransferase inhibitor (FTIs) on mitochondrial level of malaria parasites is not fully understood. In this study, therefore, the effect of a FTI R115777 on the function of mitochondria of P. falciparum was investigated experimentally. As a result, FTI R115777 was found to suppress the infection rate of malaria parasites under in vitro condition. It also reduces the copy number of mtDNA-encoded cytochrome c oxidase III. In addition, the mitochondrial membrane potential (ΔΨm) and the green fluorescence intensity of MitoTracker were decreased by FTI R115777. Chloroquine and atovaquone were measured by the mtDNA copy number as mitochondrial non-specific or specific inhibitor, respectively. Chloroquine did not affect the copy number of mtDNA-encoded cytochrome c oxidase III, while atovaquone induced to change the mtDNA copy number. These results suggest that FTI R115777 has strong influence on the mitochondrial function of P. falciparum. It may have therapeutic potential for malaria by targeting the mitochondria of parasites.
Citations
Citations to this article as recorded by
Promising Molecular Targets of Plasmodium Falciparum, the Deadliest Parasite and Their Synthetic Inhibitors: A Review Raksha Kardam, Ashok Jangra, Dinesh Kumar, Vinod Kumar, Vikas Sharma ChemistrySelect.2025;[Epub] CrossRef
Recent Advances in Diagnostics and Therapeutic Interventions for Drug-Resistant Malaria Kangkana Barman, Pranab Goswami ACS Infectious Diseases.2025; 11(6): 1296. CrossRef
Novel Therapeutics for Malaria Haitham Alaithan, Nirbhay Kumar, Mohammad Z. Islam, Angelike P. Liappis, Victor E. Nava Pharmaceutics.2023; 15(7): 1800. CrossRef
Structure- and ligand-based drug design methods for the modeling of antimalarial agents: a review of updates from 2012 onwards Vivek K. Vyas, Sapna Bhati, Shivani Patel, Manjunath Ghate Journal of Biomolecular Structure and Dynamics.2022; 40(20): 10481. CrossRef
Characterization of the promoter of the human farnesyltransferase beta subunit and the impact of the transcription factor OCT-1 on its expression Henning Verhasselt, Patrick Stelmach, Marie Domin, Dominik Jung, Anna Hagemann, Iris Manthey, Hagen S. Bachmann Genomics.2022; 114(2): 110314. CrossRef
A comprehensive review on classifying fast-acting and slow-acting antimalarial agents based on time of action and target organelle of Plasmodium sp Monika Mariebernard, Abhinab Mohanty, Vinoth Rajendran Pathogens and Disease.2022;[Epub] CrossRef
Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond S. Daisy Precilla, Shreyas S. Kuduvalli, Anitha Thirugnanasambandhar Sivasubramanian Cell Biology International.2021; 45(1): 18. CrossRef
The Repurposing of the Antimalaria Drug, Primaquine, as a Photosensitizer to Inactivate Cryptococcal Cells Uju L. Madu, Adepemi O. Ogundeji, Olufemi S. Folorunso, Jacobus Albertyn, Carolina H. Pohl, Olihile M. Sebolai Photochem.2021; 1(2): 275. CrossRef
Live and Let Dye: Visualizing the Cellular Compartments of the Malaria Parasite Plasmodium falciparum Marleen Linzke, Sun Liu Rei Yan, Attila Tárnok, Henning Ulrich, Matthew R. Groves, Carsten Wrenger Cytometry Part A.2020; 97(7): 694. CrossRef
Drug targets for resistant malaria: Historic to future perspectives Sahil Kumar, T.R. Bhardwaj, D.N. Prasad, Rajesh K. Singh Biomedicine & Pharmacotherapy.2018; 104: 8. CrossRef
The Prenylated Proteome of Plasmodium falciparum Reveals Pathogen-specific Prenylation Activity and Drug Mechanism-of-action
Jolyn E. Gisselberg, Lichao Zhang, Joshua E. Elias, Ellen Yeh Molecular & Cellular Proteomics.2017; 16(4): S54. CrossRef
Exploring the putative self‐binding property of the human farnesyltransferase alpha‐subunit Anna Hagemann, Grit Müller, Iris Manthey, Hagen S. Bachmann FEBS Letters.2017; 591(21): 3637. CrossRef
First
Prev
